Edition:
India

Eurofins Scientific SE (EUFI.PA)

EUFI.PA on Paris Stock Exchange

396.00EUR
24 Apr 2019
Change (% chg)

€12.00 (+3.12%)
Prev Close
€384.00
Open
€383.20
Day's High
€396.00
Day's Low
€381.60
Volume
60,027
Avg. Vol
45,235
52-wk High
€492.40
52-wk Low
€298.20

Latest Key Developments (Source: Significant Developments)

Eurofins Announces Buy-Back Of Minority Stake Owned By Biologists In Eurofins Laboratoire Des Pyramides
Monday, 15 Apr 2019 

April 15 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS ANNOUNCES A BUY-BACK OF A MINORITY STAKE OWNED BY BIOLOGISTS IN EUROFINS LABORATOIRE DES PYRAMIDES (FRANCE).BIOLOGISTS HAVE DECIDED TO INDIRECTLY REINVEST PART OF PROCEEDS FROM BUY-BACK OF THEIR SHARES IN EUROFINS BY SUBSCRIBING TO RESERVED CAPITAL INCREASE.EUROFINS SCIENTIFIC SE ISSUED 3,857 NEW SHARES, REPRESENTING 0.02% OF THE COMPANY’S SHARE CAPITAL.SUBSCRIPTION VIA CONTRIBUTION IN KIND OF SHARES IN EUROFINS BIOLOGIE MÉDICALE ILE DE FRANCE, WHICH THEY RECEIVED IN EXCHANGE OF MINORITY STAKE IN EUROFINS.  Full Article

Eurofins FY Adjusted EBITDA Up 29.3% YoY
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Eurofins Scientific SE ::EUROFINS DELIVERS SOLID FY 2018 RESULTS WITH REVENUES OF EUR 3,781M (+27% YOY) AND ADJUSTED EBITDA OF EUR 720M (19.0% OF REVENUES), IN LINE WITH ITS RECENTLY UPGRADED OBJECTIVES.ORGANIC GROWTH(10) WAS 4.5% IN FY 2018.BASIC ADJUSTED EARNINGS PER SHARE (EPS) INCREASED 15% TO EUR 20.11 IN FY 2018.PROPOSAL TO DISTRIBUTE A DIVIDEND OF EUR 2.88 PER SHARE.STRONG OPERATING CASH FLOW GENERATION UP 34% TO EUR 544M IN FY2018, WITH NET WORKING CAPITAL BELOW 5% OF REVENUES.INTENDS TO KEEP M&A INVESTMENTS UNDER EUR 300M PER ANNUM ON AVERAGE IN 2019 AND 2020.GROUP WILL NOW INCREASINGLY FOCUS ON OPERATIONAL PERFORMANCE OPTIMISATION, WHICH IT EXPECTS SHOULD ALSO IMPROVE ITS MARGINS AND CASH FLOW GENERATION.INTENDS TO KEEP M&A INVESTMENTS UNDER EUR 300M PER ANNUM ON AVERAGE IN 2019 AND 2020 AND MAY NOT EVEN REACH THAT LEVEL IN ABSENCE OF COMPELLING ASSETS.FOR YEAR 2019: EUR 350M FREE CASH FLOW TO FIRM.OPENING OF NEW START-UP LABORATORIES SHOULD BE MINIMAL IN 2019 AND 2020.SELF IMPOSED LIMITS OF EUR 300M EACH FOR CAPEX SPEND AND M&A SPEND IN 2019 AND 2020.EUROFINS WILL BE COMPLETING ITS FIVE YEARS INFRASTRUCTURE GLOBAL DEVELOPMENT PROGRAMME IN 2019 AND 2020.FY ADJUSTED NET PROFIT EUR 355.8 MILLION VERSUS EUR 299.1 MILLION YEAR AGO.BEYOND 2020, EUROFINS SHOULD EXPAND MOSTLY VIA ORGANIC GROWTH AND MODEST M&A ACTIVITIES UNTIL ITS LEVERAGE RATIO(15) IS BACK TO ITS HISTORIC SECULAR LEVEL..  Full Article

Eurofins Scientific Further Redeems Its EUR 300M November 2018 Eurobond And Extends Its Organic Growth Objectives Beyond 2020
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Eurofins Scientific SE ::EUROFINS FURTHER REDUCES ITS FINANCING COSTS AFTER REDEEMING ITS EUR 300M NOVEMBER 2018 EUROBOND AND EXTENDS ITS ORGANIC GROWTH OBJECTIVES BEYOND 2020.CONFIRMS ITS 2018 OBJECTIVES.CONFIRM ITS 2018 OBJECTIVES.BELIEVES THAT SETTING A SECULAR ANNUAL ORGANIC GROWTH TARGET OF 5% BEYOND 2020 IS AN ACHIEVABLE OBJECTIVE..EXPECTS TO SEE BENEFITS ON ITS ORGANIC GROWTH AND PROFITABILITY OF ITS EXCEPTIONAL 2015-2020 INFRASTRUCTURE AND IT SOLUTIONS INVESTMENT PROGRAMME.IN JANUARY 2020, EUROFINS’ EXPENSIVE HYBRID (EUR 300M, 7% FIXED COUPON) WILL BECOME CALLABLE AND THIS SHOULD ALSO PROVIDE CO WITH ANOTHER OPPORTUNITY TO FREE CASH FLOW FOR ITS INVESTMENTS AND ITS SHAREHOLDERS.  Full Article

Eurofins Acquires Laboratoire Dermscan
Monday, 29 Oct 2018 

Oct 29 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS IS REINFORCING ITS GLOBAL LEADERSHIP IN COSMETIC & PERSONAL CARE PRODUCTS TESTING WITH THE ACQUISITION OF DERMSCAN IN FRANCE.EUROFINS IS REINFORCING ITS GLOBAL LEADERSHIP IN COSMETIC & PERSONAL CARE PRODUCTS TESTING WITH THE ACQUISITION OF DERMSCAN IN FRANCE.SUCCESSFULLY CLOSED ACQUISITION OF LABORATOIRE DERMSCAN SAS.  Full Article

Eurofins Acquires Clinical Research Laboratories In North America
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS EXPANDS ITS LEADING GLOBAL COSMETIC TESTING FOOTPRINT WITH THE ACQUISITION OF CLINICAL RESEARCH LABORATORIES IN NORTH AMERICA.ANNOUNCES THAT IT HAS SUCCESSFULLY CLOSED THE ACQUISITION OF CLINICAL RESEARCH LABORATORIES LLC (“CRL”).  Full Article

Eurofins To Expand New Materials, Engineering Science Verticals With Acquisition Of Nanolab Technologies
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS TO EXPAND NEW MATERIALS AND ENGINEERING SCIENCE VERTICALS WITH THE ACQUISITION OF NANOLAB TECHNOLOGIES, CEMENTING PRESENCE IN HIGH-TECH INDUSTRIES.TRANSACTION SHOULD BE IMMEDIATELY MARGIN-ACCRETIVE FOR EUROFINS AFTER CLOSING.DEAL IS EXPECTED TO CLOSE IN THE THIRD QUARTER OF 2018.  Full Article

Eurofins Acquires Of Ecosur
Friday, 27 Jul 2018 

July 27 (Reuters) - Eurofins Scientific SE ::EUROFINS BECOMES THE MARKET LEADER IN FOOD TESTING SERVICES IN SPAIN WITH THE ACQUISITION OF ECOSUR.IT HAS SUCCESSFULLY CLOSED ACQUISITION OF LABORATORIOS ECOSUR S.A..  Full Article

Eurofins Announces The Acquisition Of Laboratoire De Bromatologie De L’Ouest
Tuesday, 3 Jul 2018 

July 3 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS ANNOUNCES THE ACQUISITION OF LABORATOIRE DE BROMATOLOGIE DE L’OUEST (LBO) EXTENDING ITS NETWORK OF FOOD TESTING LABORATORIES IN FRANCE.  Full Article

Eurofins Raises Its Revenues Objectives For 2018
Tuesday, 26 Jun 2018 

June 26 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS RAISES ITS REVENUES OBJECTIVES FOR 2018 TO EUR 3.8BN (4BN PRO-FORMA), TO 4.3BN FOR 2019 AND TO 4.7BN FOR 2020*.IN 2019 CONSOLIDATED AT MIDYEAR, EUROFINS SHOULD BE ABLE TO REPORT REVENUES* IN EXCESS OF EUR 4.3BN.FOR 2020, EUROFINS IS SETTING AN OBJECTIVE TO REACH REVENUES* IN EXCESS OF EUR 4.7BN IN 2020.ACQUISITIONS SIGNED SO FAR IN 2018 SHOULD HAVE IMPACT ON BOTH 2018 AND 2019 CONSOLIDATED EBITDA MARGIN.ACQUISITIONS SIGNED SO FAR IN 2018, LIKE THOSE OF 2017, SHOULD HAVE AN ACCRETIVE IMPACT ON BOTH 2018 AND 2019 CONSOLIDATED EBITDA MARGIN.ADJUSTED EBITDA MARGIN SHOULD CONTINUE TO IMPROVE IN 2018 AND MORE SO IN 2019 AND 2020..CONFIRMS ITS 20% ADJUSTED EBITDA MARGIN OBJECTIVE FOR 2020..SHOULD NOT REQUIRE ADDITIONAL EQUITY.NET DEBT TO PRO-FORMA ADJUSTED EBITDA LEVERAGE** SHOULD REMAIN LARGELY WITHIN ITS COVENANT.  Full Article

Eurofins: U.S. Antitrust Clearance For Covance Food Solutions Acquisition
Thursday, 21 Jun 2018 

June 21 (Reuters) - EUROFINS SCIENTIFIC SE ::EUROFINS ANNOUNCES U.S. ANTITRUST CLEARANCE FOR THE ACQUISITION OF COVANCE FOOD SOLUTIONS.EXPIRATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO ACT SATISFIES ONE OF CONDITIONS NECESSARY FOR CONSUMMATION OF ACQUISITION.ACQUISITION IS EXPECTED TO CLOSE IN Q3 OF 2018..ACQUISITION ENHANCES EUROFINS POSITION AS LEADER IN FOOD TESTING INDUSTRY IN THE U.S.  Full Article